| Drug-Induced Adverse Reactions | Lifetime | 25 | DE 4 | 99.18 |
| Clusterin in disease pathology | Lifetime | 3 | DE 1 | 98.16 |
| Biomarkers in Disease Mechanisms | Lifetime | 23 | DE 2 | 98.40 |
| Urticaria and Related Conditions | Lifetime | 78 | DE 14 | 99.01 |
| Cutaneous lymphoproliferative disorders research | Lifetime | 79 | DE 5 | 98.89 |
| Autoimmune Bullous Skin Diseases | Lifetime | 120 | DE 18 | 98.78 |
| Inflammasome and immune disorders | Lifetime | 171 | DE 10 | 98.11 |
| Cell death mechanisms and regulation | Lifetime | 297 | DE 28 | 97.65 |
| Autoimmune and Inflammatory Disorders | Lifetime | 157 | DE 10 | 97.61 |
| Dermatology and Skin Diseases | Lifetime | 641 | DE 108 | 97.07 |
| Hidradenitis Suppurativa and Treatments | Lifetime | 50 | DE 7 | 96.15 |
| Nonmelanoma Skin Cancer Studies | Lifetime | 317 | DE 32 | 96.79 |
| Cutaneous Melanoma Detection and Management | Lifetime | 529 | DE 48 | 96.48 |
| Contact Dermatitis and Allergies | Lifetime | 480 | DE 70 | 96.20 |
| Psoriasis: Treatment and Pathogenesis | Lifetime | 643 | DE 60 | 95.34 |
| Phagocytosis and Immune Regulation | Lifetime | 635 | DE 51 | 91.94 |
| IL-33, ST2, and ILC Pathways | Lifetime | 912 | DE 67 | 92.59 |
| Dermatological and COVID-19 studies | Lifetime | 240 | DE 29 | 89.69 |
| Medicine and Dermatology Studies History | Lifetime | 382 | DE 32 | 89.36 |
| Acne and Rosacea Treatments and Effects | Lifetime | 644 | DE 43 | 88.90 |
| Genetic and rare skin diseases. | Lifetime | 762 | DE 49 | 86.85 |
| Drug-Induced Adverse Reactions | 2021-2025 | 57 | DE 5 | 95.35 |
| Autoimmune Bullous Skin Diseases | 2021-2025 | 161 | DE 32 | 94.39 |
| Autoimmune and Inflammatory Disorders | 2021-2025 | 66 | DE 3 | 93.39 |
| Cutaneous Melanoma Detection and Management | 2021-2025 | 199 | DE 33 | 94.16 |
| Dermatological and COVID-19 studies | 2021-2025 | 39 | DE 2 | 90.69 |
| Urticaria and Related Conditions | 2021-2025 | 288 | DE 53 | 89.88 |
| Nonmelanoma Skin Cancer Studies | 2021-2025 | 302 | DE 36 | 88.36 |
| Cutaneous lymphoproliferative disorders research | 2021-2025 | 364 | DE 40 | 85.55 |
| Hidradenitis Suppurativa and Treatments | 2021-2025 | 192 | DE 19 | 80.97 |
| Surgical site infection prevention | 2021-2025 | 520 | DE 37 | 72.28 |
| Acne and Rosacea Treatments and Effects | 2021-2025 | 397 | DE 17 | 74.28 |
| Nail Diseases and Treatments | 2021-2025 | 703 | DE 36 | 74.68 |
| Contact Dermatitis and Allergies | 2021-2025 | 651 | DE 73 | 75.26 |
| Oral Health Pathology and Treatment | 2021-2025 | 894 | DE 25 | 71.90 |
| Medicine and Dermatology Studies History | 2021-2025 | 166 | DE 13 | 63.32 |
| Parvovirus B19 Infection Studies | 2021-2025 | 778 | DE 39 | 58.03 |
| Chemotherapy-related skin toxicity | 2021-2025 | 871 | DE 35 | 28.43 |
